Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotech advancing novel therapies for fibro-inflammatory diseases. This news hub provides investors and researchers with essential updates on nebokitug (CM-101), the company's lead monoclonal antibody targeting CCL24 in conditions like primary sclerosing cholangitis (PSC) and systemic sclerosis.
Access timely reports on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes verified updates from Phase 2/3 trials, FDA/EMA designations, and scientific conference presentations. Key focus areas span biomarker validation, trial enrollment status, and intellectual property developments.
This resource serves as your central source for tracking Chemomab's progress in addressing high-need rare diseases. Bookmark this page for direct access to primary documents including SEC filings, peer-reviewed data publications, and official press releases. Check regularly for updates on the upcoming Phase 3 PSC trial and expansion into new fibrotic disease indications.
Chemomab Therapeutics, Ltd. (CMMB) reported its fourth quarter and full-year 2021 financial results, showcasing a cash position of $61.2 million compared to $11.8 million in 2020. R&D expenses rose to $2.4 million for Q4 and $6.3 million for the year, while G&A expenses increased to $2.6 million for Q4 and $6.0 million for the year. The net loss was $5.0 million for Q4, totaling $12.5 million for 2021. Significant clinical program revisions were announced, aimed at optimizing the development of CM-101, including expanded trials for PSC and SSc, with more data readouts expected over the next 24 months.
Chemomab Therapeutics (CMMB) will announce its fourth quarter and full year 2021 financial results on March 9, 2022. The company focuses on developing therapeutics for fibrotic and inflammatory diseases. A conference call will be held at 8:00 a.m. Eastern Time to discuss performance and upcoming events. Chemomab's key product, CM-101, is currently undergoing two Phase 2 trials with a third set to start in early 2022. This innovative approach targets the CCL24 protein, which is central to fibrosis and inflammation.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, announced it will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, highlighting its monoclonal antibody CM-101, designed to block the soluble protein CCL24, which is linked to these conditions. CM-101 is currently undergoing two Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a third trial in systemic sclerosis anticipated to start in early 2022.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced the appointment of Jack Lawler as Vice President of Global Clinical Development Operations, enhancing its clinical development leadership. Lawler brings over 22 years of experience in drug development, previously contributing to eight approved pharmaceuticals. Chemomab has also expanded its facilities in Tel Aviv to support anticipated growth. The company focuses on developing CM-101, a monoclonal antibody aimed at addressing serious fibrotic and inflammatory diseases, currently in two Phase 2 trials.
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced participation in two key virtual events: the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022, offering an on-demand corporate overview webcast. Chemomab focuses on therapeutics for fibrotic and inflammatory diseases, with its lead candidate, CM-101, in Phase 2 trials targeting multiple severe conditions. For event registration and additional details, visit Chemomab's website.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) has announced that CEO Dale R. Pfost will take on the role of Chairman, pending shareholder approval expected in February 2022. Stephen Squinto will step down from his role as Chairman and director on December 19, 2021. Dr. Pfost expressed excitement for the company's Phase 2 clinical programs in liver fibrosis and systemic sclerosis. Chemomab is developing CM-101, a monoclonal antibody targeting CCL24, currently undergoing clinical trials for severe fibrotic and inflammatory diseases.
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) announced the appointment of David M. Weiner, MD, as Interim Chief Medical Officer, effective immediately. He replaces Dr. Arnon Aharon, who will remain for a 60-day transition period. Dr. Weiner brings over 25 years of biopharmaceutical experience and has held senior roles at various biotech companies. He aims to advance Chemomab's clinical programs, particularly for CM-101, a monoclonal antibody in Phase 2 trials targeting fibrotic diseases. The company acknowledges Dr. Aharon's contributions to its clinical advancements.
Chemomab Therapeutics (CMMB) announced its third-quarter financial results for 2021, revealing a significant cash position of $64.3 million, which is expected to fund operations until mid-2023. The company reported a net loss of $3.0 million, or ($0.01) per share, compared to a loss of $1.2 million in the previous year. Key updates included advancements in clinical trials for CM-101 aimed at treating fibrotic diseases and the appointment of Donald Marvin as CFO. Upcoming data readouts from ongoing Phase 2 trials are anticipated in 2022, suggesting potential growth for Chemomab's pipeline.
Chemomab Therapeutics (Nasdaq: CMMB) announced a poster presentation at The Liver Meeting 2021, showcasing its research on CCL24's role in Primary Sclerosing Cholangitis (PSC). The study highlights the high expression of CCL24 in PSC liver biopsies and the efficacy of the monoclonal antibody CM-101 in reducing liver injury in preclinical models. CM-101 is currently in Phase 2 trials targeting PSC and other fibrotic diseases. The company's advancements provide promising insights into potential treatment avenues.
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech firm, will host a presentation and participate in 1-on-1 investor meetings at Stifel's 2021 Virtual Healthcare Conference on November 15, 2021, at 8:00 AM ET. Dr. Dale Pfost (CEO) and Dr. Adi Mor (CSO) will present. Chemomab specializes in innovative therapeutics for fibrotic and inflammatory diseases, focusing on CM-101, an antibody targeting CCL24. This candidate shows promise in treating severe fibrotic diseases and is currently in Phase 2 trials.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
